Find Ramatroban manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 116649-85-5, Baynas, Bay u3405, Bay u 3405, Bay-u-3405, Bay-u 3405
Molecular Formula
C21H21FN2O4S
Molecular Weight
416.5  g/mol
InChI Key
LDXDSHIEDAPSSA-OAHLLOKOSA-N
FDA UNII
P1ALI72U6C

Ramatroban
Ramatroban has been used in trials studying the treatment of Asthma.
1 2D Structure

Ramatroban

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
3-[(3R)-3-[(4-fluorophenyl)sulfonylamino]-1,2,3,4-tetrahydrocarbazol-9-yl]propanoic acid
2.1.2 InChI
InChI=1S/C21H21FN2O4S/c22-14-5-8-16(9-6-14)29(27,28)23-15-7-10-20-18(13-15)17-3-1-2-4-19(17)24(20)12-11-21(25)26/h1-6,8-9,15,23H,7,10-13H2,(H,25,26)/t15-/m1/s1
2.1.3 InChI Key
LDXDSHIEDAPSSA-OAHLLOKOSA-N
2.1.4 Canonical SMILES
C1CC2=C(CC1NS(=O)(=O)C3=CC=C(C=C3)F)C4=CC=CC=C4N2CCC(=O)O
2.1.5 Isomeric SMILES
C1CC2=C(C[C@@H]1NS(=O)(=O)C3=CC=C(C=C3)F)C4=CC=CC=C4N2CCC(=O)O
2.2 Other Identifiers
2.2.1 UNII
P1ALI72U6C
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9-carbazole Propanoic Acid

2. Bay U 3405

3. Bay U 3406

4. Bay U-3405

5. Bay U3405

2.3.2 Depositor-Supplied Synonyms

1. 116649-85-5

2. Baynas

3. Bay U3405

4. Bay U 3405

5. Bay-u-3405

6. Bay-u 3405

7. 3-[(3r)-3-[(4-fluorophenyl)sulfonylamino]-1,2,3,4-tetrahydrocarbazol-9-yl]propanoic Acid

8. (+)-(3r)-3-(p-fluorobenzenesulfonamido)-1,2,3,4-tetrahydrocarbazole-9-propionic Acid

9. P1ali72u6c

10. (r)-3-(3-(4-fluorophenylsulfonamido)-3,4-dihydro-1h-carbazol-9(2h)-yl)propanoic Acid

11. 9h-carbazole-9-propanoic Acid, 3-[[(4-fluorophenyl)sulfonyl]amino]-1,2,3,4-tetrahydro-, (3r)-

12. En-137774

13. Chembl361812

14. Ncgc00167519-01

15. En 137774

16. Bay U 3406

17. Bay U-3405

18. (3r)-3-[[(4-fluorophenyl)sulfonyl]amino]-1,2,3,4-tetrahydro-9h-carbazole-9-propanoic Acid

19. Dsstox_cid_26685

20. Dsstox_rid_81819

21. Dsstox_gsid_46685

22. [3h]ramatroban

23. [3h]baynas

24. Baynas (tn)

25. Cas-116649-85-5

26. Ramatroban (jan/inn)

27. Ramatroban [inn:ban]

28. Unii-p1ali72u6c

29. 3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9-carbazole Propanoic Acid

30. [3h]bay U 3405

31. [3h]bay U3405

32. 3r-[[(4-fluorophenyl)sulfonyl]amino]-1,2,3,4-tetrahydro-9h-carbazole-9-propanoic Acid

33. (3r)-3-(((4-fluorophenyl)sulfonyl)amino)-1,2,3,4-tetrahydro-9h-carbazole-9-propanoic Acid

34. 9h-carbazole-9-propanoic Acid, 3-(((4-fluorophenyl)sulfonyl)amino)-1,2,3,4-tetrahydro-, (3r)-

35. Mfcd00887606

36. Ramatroban [mi]

37. Ramatroban [inn]

38. Ramatroban [jan]

39. Ramatroban [mart.]

40. 9h-carbazole-9-propanoic Acid, 3-(((4-fluorophenyl)sulfonyl)amino)-1,2,3,4-tetrahydro-, (r)-

41. Ramatroban [who-dd]

42. Ramatroban (bay U3405)

43. Schembl29030

44. Mls006010637

45. Gtpl1910

46. Gtpl1911

47. Dtxsid1046685

48. Chebi:32087

49. Hms3648e21

50. Bay U3405;bay-u3405

51. Ex-a4208

52. Hy-b0745

53. Zinc3798772

54. Tox21_112516

55. Ac-719

56. Bdbm50161746

57. S5286

58. Akos015966619

59. Ramatroban, >=98% (hplc), Solid

60. Tox21_112516_1

61. Ccg-268842

62. Db13036

63. Ks-1310

64. Ncgc00167519-02

65. Ncgc00167519-04

66. Ncgc00167519-07

67. Smr002530322

68. R0144

69. D01128

70. 649f855

71. A803658

72. Sr-01000883932

73. Sr-01000946208

74. J-003466

75. Sr-01000883932-1

76. Sr-01000946208-1

77. Q10357327

78. (r)-3-(3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydrocarbazol-9-yl)propanoic Acid

79. (r)-3-(3-(4-fluorophenylsulfonamido)-3,4-dihydro-1h-carbazol-9(2h)-yl)propanoicacid

80. [(4-fluorophenyl)sulfonylamino] 3-(1,2,3,4-tetrahydrocarbazol-9-yl)propanoate

81. 3(r)-[[(4-fluoro-phenyl) Sulfonyl]amino]-1,2,3,4-tetrahydro-9h-carbazole-9-propanoic Acid

82. 3-[(r)-3-(4-fluoro-benzenesulfonylamino)-1,2,3,4-tetrahydro-carbazol-9-yl]-propionic Acid

83. A8x

2.4 Create Date
2005-06-24
3 Chemical and Physical Properties
Molecular Weight 416.5 g/mol
Molecular Formula C21H21FN2O4S
XLogP32.9
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count6
Rotatable Bond Count6
Exact Mass416.12060649 g/mol
Monoisotopic Mass416.12060649 g/mol
Topological Polar Surface Area96.8 Ų
Heavy Atom Count29
Formal Charge0
Complexity689
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Pharmacology and Biochemistry
4.1 MeSH Pharmacological Classification

Platelet Aggregation Inhibitors

Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)


ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty